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Abstract
Purpose Bone metastasis from hepatocellular carcinoma
(HCC) can present with soft tissue formation, resulting in
oncologic emergency. Contrast-enhanced FDG PET/CT and
bone scintigraphy were compared to evaluate characteristics
of bone metastases with or without soft tissue formation
from HCC.
Methods Of 4,151 patients with HCC, 263 patients had
bone metastases. Eighty-five patients with bone metastasis
from HCC underwent contrast-enhanced FDG PET/CT.
Fifty-four of the enrolled subjects had recent 99mTc-HDP
bone scintigraphy available for comparison. Metastatic
bone lesions were identified with visual inspection on
FDG PET/CT, and maximum standardized uptake value
(SUVmax) was used for the quantitative analysis. Confir-
mation of bone metastasis was based on histopathology,
combined imaging modalities, or serial follow-up studies.
Results Forty-seven patients (55%) presented with soft
tissue formation, while the remaining 38 patients presented
without soft tissue formation. Frequent sites of bone
metastases from HCC were the spine (39%), pelvis (19%),
and rib cage (14%). The soft-tissue-formation group had
more frequent bone pain (77 vs. 37%, p<0.0001), higher
SUVmax (6.02 vs. 3.52, p<0.007), and higher incidence of
photon defect in bone scintigraphy (75 vs. 0%) compared to
the non-soft-tissue-formation group. FDG PET/CT had
higher detection rate for bone metastasis than bone
scintigraphy both in lesion-based analysis (98 vs.
53%, p=0.0015) and in patient-based analysis (100 vs.
80%, p<0.001).
Conclusions Bone metastasis from HCC showed a high
incidence of soft tissue formation requiring emergency
treatment. Although the characteristic findings for soft
tissue formation such as photon defect in bone scintigraphy
are helpful in detection, overall detectability of bone
metastasis is higher in FDG PET/CT. Contrast-enhanced
PET/CT will be useful in finding and delineating soft-
tissue-forming bone metastasis from HCC.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most
common solid malignancies in the world, and its prevalence
is higher in Asian countries [1]. HCC accounts for over
80% of all primary liver cancers, which rank fourth among
cancer-related deaths worldwide [2]. The incidence of
extrahepatic metastases from HCC was reported to be
37% with the following order of frequency: the lung, lymph
nodes, and bone [3]. The extrahepatic metastases occur in
advanced stages, and an accurate diagnosis of extraheptic
metastases is of great value for determining the therapeutic
modality at an early stage [4].
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Bone metastasis from HCC is not uncommon, and the
incidence has been increasing [5, 6]. A recent study
reported that patients with isolated bone metastasis showed
longer survival than those with metastases in bone and
other sites [7]. Meanwhile, bone metastases-associated
expansile soft tissue mass and bony destruction can cause
clinical emergencies such as severe pain, spinal cord
compression, and paralysis. Therefore, immediate operation
or radiation therapy should be considered in bone metas-
tasis with soft tissue formation [8–10]. However, the
clinical importance of bone metastasis from HCC-
originated soft tissue components has been underestimated
due to the low incidence in Western countries.
99mTc-MDP or HDP bone scintigraphy (BS) has been
widely used to detect bone metastasis in most malignancies.
Due to the osteolytic nature of bone metastasis from HCC,
the detectability of BS has been reported to be lower
compared with cancers with osteoblastic metastasis [11–
13]. Bony destruction resulting from osteolytic metastasis
can present with photon defects in BS [14–16], but the
correlation with 18F-fluoro-2-deoxy-D-glucose (FDG) PET/
CT has not been explored.
FDG PET/CT has been known to be less suitable for
primary HCC due to limited detectability [17]. However,
several studies reported that PET or PET/CT is useful for
detection of extrahepatic metastases from HCC [18–21].
Moreover, PET/CT showed higher sensitivity for the
detection of bone metastasis than other extrahepatic
metastases from HCC [22]. The aim of the present study
is to evaluate the feasibility of FDG PET/CT for assessing
bone metastasis from HCC and to describe imaging
characteristics of bone metastases from HCC according to
the presence of soft tissue formation.
Materials and Methods
Patients
We reviewed 4,151 patients diagnosed with HCC between
January 2005 and December 2010. Of the 263 patients
confirmed to have bone metastasis, 103 patients underwent
contrast-enhanced PET/CT for the evaluation of suspicious
bone metastasis and/or other extrahepatic metastasis. In our
institute, contrast-enhanced PET/CT is routinely performed
in most patients with HCC when extrahepatic metastases
are suspected based on laboratory examinations, clinical
symptoms, CT, and other imaging modalities. Eighteen
patients were excluded from the study for the following
reasons: 13 patients had diffuse bone metastases; 2 patients
had double primary; and 3 patients were not confirmed as
having bone metastasis. Ultimately, a total of 85 patients
were included in this study.
Contrast-Enhanced FDG PET/CT
All patients were instructed to fast for 8 h except for
glucose-free oral hydration before the PET examination,
and the blood glucose concentration was measured and
confirmed to be less than 140 mg/dL. Intravenous injec-
tions of 5.5 MBq of 18F-FDG per kilogram of body weight
were administered. All patients were kept lying comfortably
during the 60 min uptake period and voided before being
supinely positioned on the scanner table. Integrated FDG
PET/CT scanning was performed using a combined PET/
CT scanner (Discovery STE; GE Healthcare, Milwaukee,
WI). Sixty minutes after the 18F-FDG injection, the first
unenhanced CT scan with eight-slice scanner was per-
formed from the vertex of the skull through the mid-thigh
using the following parameters: 120 kVp; 30 mA; 0.8 s
rotation time; 3.75 mm helical thickness; 27 mm per
rotation (speed); 2.5 mm scan reconstruction, with a
reconstruction index of 1.25 mm; 15.7 cm field of view;
and a 512×512 matrix. A PET scan was then acquired from
the level of the ear through the mid-thigh in three-
dimensional mode at 2.5 min per bed position. The PET
unit had an axial field of view of 50 cm and a spatial
resolution of 4.29 mm in full width of half maximum at
1 cm from the center. PET data were reconstructed
iteratively using an ordered-subset expectation maximiza-
tion algorithm. After finishing PET scans, 2 ml/s of contrast
medium (Omnipaque 300, GE Healthcare) was injected,
and a contrast-enhanced CT scan of the same imaging field
was obtained immediately at 120 kVp and 230 mA, with a
helical thickness of 3.75 mm, 60 s. The reconstructed CT,
PET, and fused PET/CT images were displayed in axial,
sagittal, and coronal planes.
Contrast-enhanced PET/CT was interpreted by two
experienced nuclear medicine physicians (who had 3–
4 years of experience with contrast-enhanced PET/CT)
without knowledge of the patient’s clinical history. A bone
lesion on PET/CT was regarded as bone metastasis if two
nuclear medicine physicians agreed that there was abnor-
mally increased FDG uptake compared with background
bone marrow and osteolytic/osteoblastic change with/
without bony destruction on bone window setting CT.
A region of interest (ROI) was placed over all suspected
bone lesions to measure maximum intensity in each lesion
for semi-quantitative analysis. The standardized uptake
value (SUV) was calculated by using the following
formula: radioactivity concentration in the region of interest
(Bq/ml)/(injected dose of FDG/body weight in grams). The
value of SUVmax of metastatic bone lesion was not used for
the visual interpretation.
On contrast-enhanced CT as part of PET/CT, the
presence of the soft-tissue component was evaluated using
CT attenuation values (Hounsfield units). Soft tissue
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formation was determined by reviewing nonenhanced and
contrast-enhanced CT. Bone destructive lesion with soft
tissue density that was well-enhanced by contrast dye was
considered soft tissue formation (Fig. 1).
Tc-99m HDP Bone Scintigraphy
Bone scintigraphy was performed using a dual-head
gamma camera (ADAC Dual genesys, ADAC Laborato-
ries, Milpitas, CA) equipped with general-purpose colli-
mators. Anterior and posterior whole-body images were
acquired approximately 3 h after intravenous administra-
tion of 925 MBq 99mTc-hydroxymethane diphosphonate
(HDP). Additional static planar images were acquired at
the discretion of the attending nuclear physician. Single
photon emission computed tomography was not per-
formed routinely.
Bone scintigraphy was interpreted by two experienced
nuclear medicine physicians (who had 3–4 years of
experience with bone scintigraphy) without knowledge of
the patient’s clinical history. A bone lesion on bone
scintigraphy was considered as significant if it showed
abnormal uptake excluding lesions interpreted as arthritis,
osteophytes, or benign compression fracture. A lesion with
a central cold defect was considered to be a malignant
lesion [23, 24].
Determination of Bone Metastasis
Confirmation of bone metastasis by biopsy was available in
18 patients. All other lesions not confirmed by biopsy were
considered to be true-positive findings if at least one of the
following criteria was satisfied: (1) serial PET/CT scans
(obtained at 3–6 month follow-up; 11 patients) showing
increasing lesion size and/or FDG accumulation, (2)
positive findings of bone metastasis on concomitant or
follow-up MR finding (23 patients), (3) serial CT findings
of osteolytic and/or destructive changes (15 patients), (4)
osteolytic/osteoblastic lesions with abnormally increased
FDG uptake and/or expansile or erosive cortical changes
present on contrast-enhanced PET/CT (6 patients), (5)
concomitant or follow-up bone scintigraphy findings with
bone involvement (22 patients) [7]. Ten patients were
confirmed based on more than two criteria.
Statistical Analysis
All data were analyzed using statistical software (Medcalc
Software, Mariakerke, Belgium). The mean age of men and
women was compared using the independent-sample t test.
The χ2 test was used to compare the patients’ background
characteristics and symptoms. Survival rate was evaluated
by the Kaplan-Meier method, and the log-rank test was
used to compare survival rates. An alternative-free response
receiver operating characteristic (ROC) curve was analyzed
to find the cut-off value of bone metastasis with soft-tissue
component. P<0.05 was considered statistically significant.
Results
Patient Characteristics
A total of 85 patients were enrolled in the present study (70
male and 15 female patients, mean age 58 years). Among
the 85 patients, 47 were diagnosed as having soft tissue
formation, and 38 were diagnosed as having no soft tissue
formation. Demographic characteristics of each group are
displayed in Table 1. Presence of viral infection, serum α-
fetoprotein (AFP) level, Child-Pugh class, histopathologic
A B C
Fig. 1 Determination of soft tissue formation by contrast-enhanced
CT, precontrast CT, and FDG PET/CT. A 65-year-old man diagnosed
with hepatocellular carcinoma had severe bone pain on T-spine level. a
Contrast-enhanced CT revealed bone metastasis with soft-tissue
component involving T2 and left posterior second rib. This mass
compressed the spinal cord and nerve root causing severe pain and
paralysis. b Precontrast CT of bone window setting showed osteolytic
and destructive bony lesion. c Hypermetabolism in T2 vertebra and
left posterior second rib is well visualized on fused PET/CT. The
patient had the T2 vertebra debulked in an emergency operation
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differentiation, combined extrahepatic metastasis, and iso-
lated bone metastasis were compared between the soft-
tissue-forming group and non-forming group, but no
significant difference was found.
The soft-tissue-forming group showed higher preva-
lence of bone pain than the non-forming group (37 vs.
77%, P<0.0001).
Bone Metastasis Site Distribution
A total of 211 bone metastatic sites were detected. Of 211
sites, 81 lesions (38%) were classified as soft-tissue-
forming metastasis. The regional distribution of bone
metastatic sites is listed in Table 2. The frequent sites of
bone metastasis from HCC were the spine (n=100, 48%) ,
followed by pelvis (n=40, 19%) and rib cage (n=30, 14%).
There was no significant difference in the affected sites
between the soft-tissue-forming group and the non-forming
group, except for the high frequency of soft-tissue-forming
metastasis in the rib cage (Fig. 2).
Detection Rate by FDG PET/CT and 99mTc-HDP Bone
Scintigraphy
Comparison of detection rate between FDG PET/CT and
bone scintigraphy was performed in 54 patients who
underwent both procedures (Table 3). On a lesion-based
analysis, the detection rate of FDG PET/CTwas 98% (134/
Soft tissue component
Absent Present P value
Number of patients 38 47
Gender
Male 30 40 0.650
Female 8 7
Age (years) 57 (29–75) 58 (32–82) 0.480
Hepatitis
B 30 34 0.745
C 3 4
Non-B and non-C 5 9
AFP (IU/ml) 11,391 (1–83,000) 15,688 (2–377,768) 0.846
Child-Pugh class
A 36 43 0.287
B 1 4
C 1 0
Bone pain
Yes 12 36 <0.0001*
No 25 11
SUVmax 3.52±2.74 6.02±3.56 0.007*
Differentiation of primary HCC
Well differentiated 1 1 0.996
Moderately differentiated 6 7
Poorly differentiated 7 9
Not applicable 23 30
Survival (years) 6.75 (0.4–23) 6.97 (0.4–28) 0.879
Extrahepatic metastasis except bone
Lung 4 3 0.314
LN 8 5
Lung and LN 1 2
Lung and other organ 0 3
LN and other organ 2 2
Other organ 3 5
Total 18 20
Isolated bone metastasis 20 (53%) 27 (57%)
Table 1 Characteristics of
patients with bone metastasis
from hepatocellular carcinoma
according to the presence of soft
tissue formation
Values are number, median
(range), or mean ± SD
*Significant difference between
two groups (P<0.05)
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137). FDG PET/CT detected all the lesions in the soft-
tissue-forming group (detection rate 100%, 53/53). Three
lesions without soft tissue components were missed on
FDG PET/CT. On bone scintigraphy, 73 lesions were
detected (detection rate 53%, 73/137) regardless of soft-
tissue components. Missed lesions on bone scintigraphy
were mostly bone marrow lesions (n=37) and small lesions
with a soft-tissue component less than 3 cm in diameter (n=
12). The detection rate of FDG PET/CT was significantly
higher than that of bone scintigraphy (P<0.001). There was
no statistically significant difference in detection rate
according to the presence of soft tissue formation.
On a patient-based analysis, FDG PET/CT had an
overall higher detection rate than bone scintigraphy
A B C
FED
Fig. 2 A 73-year-old man with hepatitis C virus diagnosed with
hepatocellular carcinoma with severe bone pain in the right rib cage.
a–c Bone scintigraphy failed to detect the bone metastasis. d Contrast-
enhanced CT as part of FDG PET/CT revealed bone metastasis with
well-marginated soft-tissue mass involving the axillary portion of the
right fourth rib. e Precontrast CTof bone window setting showed mass
lesion encasing the right fourth rib. f Hypermetabolism in the right
fourth rib is well visualized on fused PET/CT
Table 2 Distribution of bone metastasis sites from hepatocellular
carcinoma according to the presence of soft tissue formation
Distribution Soft tissue component Total
Absent Present
Cervical spine 8 3 11
Thoracic spine 28 12 40
Lumbar spine 20 11 31
Sacrum 10 8 18
Pelvis 27 13 40
Rib cage 10 20 30
Humerus 2 1 3
Femur 11 4 15
Scapula/clavicle 8 6 14
Skull 2 3 5
Sternum 4 0 4
Total 130 81 211
Table 3 Comparison of the detection rate [detected lesions/total
lesions (%)] between 18F-FDG PET/CT and 99mTc-HDP bone
scintigraphy to reveal bone metastasis from HCC
PET/CT Bone scintigraphy P
Lesion-based analysis
Soft tissue absent 81/84 (96%) 45/84 (54%) <0.001*
Soft tissue present 53/53 (100%) 28/53 (53%) <0.001*
Total 134/137(98%) 73/137(53%) <0.001*
Patient-based analysis
Soft tissue absent 24/24 (100%) 16/24 (67%) 0.007*
Soft tissue present 30/30 (100%) 27/30 (90%) 0.236
Total 54/54 (100%) 43/54 (80%) 0.0015*
*Significant difference between two groups (P<0.05)
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(detection rate, 100 vs. 80%), but the difference was
significant only in the non-soft-tissue-forming group.
Diagnostic Value of Mean SUVmax
SUVmax was significantly higher in the soft-tissue-forming
group than the non-forming group (Fig. 3, 6.02±3.58 vs.
3.52±2.37). ROC curve revealed the cut-off value of 3.7
SUVmax to predict a soft-tissue component but did not
reach statistical significance (area under curve 0.723,
sensitivity 66.7%, and specificity 68.5%).
Photon Defect on 99mTc-HDP Bone Scintigraphy
Typical 99mTc-HDP bone scintigraphic finding suggestive of
soft tissue formation was defined as photon defect with
marginal increased uptake (Fig. 4). Of the 28 soft tissue
lesions, typical findings were detected in 21 lesions on bone
scintigraphy (75%), and the most frequent sites were rib
cage and spine (Tables 4, 5).
Discussion
The incidence of HCC is increasing in countries where
hepatitis B or C virus is endemic [6]. The present study
enrolled a relatively large number of patients with bone
metastases from HCC and showed better detectability of
FDG PET/CT than bone scintigraphy. In addition, we
focused on the high prevalence of soft-tissue-forming
metastasis in HCC, which is consistent with previous
reports [8, 10, 25].
The incidence of bone metastasis in HCC has been
reported to be 6–10% [7, 26]. The relatively low frequency
of bone metastasis from HCC is thought to be related to the
fact that most bone metastatic lesions from HCC are
osteolytic metastases, which could be missed with conven-
tional bone scintigraphy [27]. However, because FDG PET
evaluates the tumor cells in bone metastatic lesions rather
than osteoblastic reaction, it is expected to be more
sensitive than bone scintigraphy. The incidence of bone
metastasis measured by FDG PET in our study was 5.5%,
which is consistent with the incidences in the literature.
However, one recent study reported that the frequency of
bone metastasis from HCC was 19% [7], therefore more
studies enrolling larger study groups will be needed to
assess the prevalence of bone metastasis from HCC.
Bone metastasis from HCC has the unique characteristic
of a high incidence of soft tissue formation. Fukutomi et al.
reported that 24 out of 29 lesions (83%) showed osteolysis
with expansile soft tissue formation [5]. Kim et al. reported
54% of HCC cases showed soft tissue formation [28], and
our study showed 55% of HCC cases showed soft tissue
formation on patient-based analysis. Despite the relatively
low incidence of bone metastasis, soft tissue formation
requiring emergency treatment is frequently observed in
HCC, and imaging studies to assess soft tissue formation
can be of great clinical importance. Although patients with
bone metastasis had markedly elevated AFP, the levels of
AFP were not significantly different between the soft-
tissue-forming group and the non-forming group in this
study. Clinically, the soft-tissue-forming group suffered
more bone pain and had higher SUV levels than the non-
forming group. According to the results of this study, it is
recommended that lesions with symptomatic pain and high
SUV level on FDG PET should be carefully examined to
determine the presence of soft tissue formation.
99mTc-MDP or HDP bone scintigraphy has been widely
used as a diagnostic modality for screening patients with
suspicious metastatic bone disease from various malignan-
cies for decades. However, osteolytic lesions may not be
detected on bone scintigraphy, and it has been known to be
the pitfall of bone scintigraphy [25, 29]. In this study, all
bone metastases from HCC were osteolytic, and the
detection rate of bone scintigraphy was low. As is well-
known, the detection rate of bone scintigraphy for HCC is
much lower than those of breast cancer [11] and lung
cancer [30]. However, the characteristic findings of photon
defects in soft-tissue-forming lesions can be helpful when
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Fig. 3 Box plots show the distribution of SUVmax in the bone
metastasis groups according to the presence of a soft tissue
component. The mean (SD) SUVmax was 3.52±2.37 for the bone
metastasis group without a soft tissue component and 6.02±3.58 for
bone metastasis group with a soft tissue component (p<0.001).
Outside value* indicates a value that is larger than the upper quartile
plus 1.5 times the interquartile range
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evaluated for osteolytic metastasis in bone scintigraphy. In
this study, photon defect was frequently found on soft-
tissue-forming lesions with an incidence of 75%. Photon
defect is a well known finding on bone scintigraphy that
can be observed in osteolytic metastasis [14–16], and we
demonstrated that photon defect on bone scintigraphy in
A B C
D
Fig. 4 A 72-year-old man diagnosed with hepatocellular carcinoma
with a history of transarterial catheter embolization. During follow-up,
the patient complained of bone pain in the left proximal femur with
elevated AFP (6,911.73 IU/ml). a PET/CT showed increased FDG
uptake at the left proximal femur. b Whole-body bone scintigraphy
shows bone metastasis with photon defect with marginal increased
HDP uptake at left proximal femur. Another focal uptake at the
costochondral junction of the left eighth rib was a traumatic lesion. c–
d Axial view of contrast-enhanced CT and PET/CT shows the bone
metastasis with soft tissue component at the left proximal femur
Table 4 Distribution of photon defect on 99mTc-HDP bone
scintigraphy
Distribution Photon defect with marginal
increased uptake
Cervical spine 1
Thoracic spine 1
Lumbar spine 1
Sacrum 3
Pelvis 4
Rib cage 5
Scapula 2
Femur 2
Skull 1
Total 21
Table 5 Comparison of bone metastasis with/without soft tissue
formation according to findings of 99mTc-HDP bone scintigraphy
Finding of bone scintigraphy Soft tissue component
Absent Present
Photon defect with marginal
increased uptake
0 (0%) 21 (75%)
Abnormally increased uptake 45 (100%) 7 (25%)
Total 45 28
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HCC is directly related to a high prevalence of soft tissue
formation.
Overall, the detection rate of FDG PET was superior to
bone scintigraphy in the present study. FDG PET has
limitations for the diagnosis of primary HCC because of
high levels of glucose-6-phosphatase in HCCs, especially in
well-differentiated tumors [31–33]. Only a few studies have
assessed the diagnostic accuracy of FDG PET in bone
metastasis from HCC [34]. Although this study compared
detection rates of FDG PET and whole-body bone scintig-
raphy in selected patients with known bone metastasis, the
overall diagnostic accuracy is expected to be higher in FDG
PET than bone scintigraphy. Three lesions missed on FDG
PET/CT were all pure osteolytic without increased FDG
uptake, probably due to recent chemotherapy.
We found in our study that 47 out of 85 (55%) of our
patients had isolated bone metastasis, which is consistent
with a previous study by Ho et al. They reported that
isolated bone metastasis in HCC might not be as uncom-
mon as previously believed, and more common than
metastasis to other regions [7]. As is well known, whole
body screening with FDG PET or bone scintigraphy is
crucial in screening for bone metastasis, and these imaging
studies should be considered even in patients without other
soft tissue metastasis.
In the present study, six patients with soft tissue
formation underwent emergency operation due to impend-
ing cord compression and paralysis (data not presented).
Non-contrast CT as part of PET/CT can find the destruction
of cortex but is limited in delineating the expanding pattern
escaping from bone. FDG uptake on soft tissue lesion
detected on nonenhanced CT might be the clue to soft-
tissue formation. Furthermore, contrast-enhanced CT is
routinely performed in most oncologic PET/CT studies in
our institute and was performed in all the patients enrolled
in this study. Contrast-enhanced CT was especially useful
for the evaluation of the extension to the nerve and adjacent
tissue, which could be a guideline for further studies
including MRI and for the treatment plan.
There were several limitations in this study. Not all of the
lesions were confirmed by histopathology. However, this is
a well-known limitation of most studies assessing bone
metastases, and a clinical decision can be made without
pathology confirmation when typical imaging findings are
present [3]. Second, the study group comprised a heteroge-
neous group of patients for staging and follow-up. Forty-
four of them had previous treatment history of radiotherapy,
chemotherapy, liver resection, transcatheter arterial infusion
chemotherapy, and/or radiofrequency ablation therapy. This
can be a limitation of evaluation of bone metastasis. Third,
only subjects who underwent FDG PET/CT were selected
from a total of 263 patients diagnosed with bone metastasis
from HCC. Possible selection bias cannot be excluded.
In conclusion, the incidence of bone metastases from
HCC is not uncommon, and high incidence of soft tissue
formation has unique imaging and clinical characteristics.
Although FDG PET was superior to bone scintigraphy in
the detection of bone metastasis, bone scintigraphy could
be used for screening and for identifying soft-tissue-
forming metastasis. Detection of expanding soft tissue
lesions on nonenhanced CT, high FDG uptake on areas of
soft tissue density, and photon defect on bone scintigraphy
were considered as possible indicators of soft-tissue-
forming bone metastasis, and enhanced CT for identifica-
tion of enhancing mass lesions could aid in diagnosis.
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